CTLA4 and cancer: Immunotherapy is emerging as an important modality in the treatment of cancer, such as ICB targeting CTLA-4 and PD-1 and its ligand (PD-L1), which can be used to treat tumors by reactivating anti-cancer immune responses (Petitprez et al., 2020).